First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex.
- Published In:
- Antiviral research, 242, 106259 (2025)
- Authors:
- Mafi, Sarah, Poyet, Jean-Luc, Alain, Sophie, Ligat, Gaëtan, Hantz, Sébastien
- Database ID:
- RPEP-12389
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12389APA
Mafi, Sarah; Poyet, Jean-Luc; Alain, Sophie; Ligat, Gaëtan; Hantz, Sébastien. (2025). First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex.. Antiviral research, 242, 106259. https://doi.org/10.1016/j.antiviral.2025.106259
MLA
Mafi, Sarah, et al. "First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex.." Antiviral research, 2025. https://doi.org/10.1016/j.antiviral.2025.106259
RethinkPeptides
RethinkPeptides Research Database. "First evidence of efficacy of peptides targeting the pUL56-p..." RPEP-12389. Retrieved from https://rethinkpeptides.com/research/mafi-2025-first-evidence-of-efficacy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.